Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit.
10.1097/CM9.0000000000001767
- Author:
Zhan-Qi WEI
1
;
Yue-Wei ZHANG
2
Author Information
1. School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China.
2. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
- Publication Type:Review
- MeSH:
Carcinoma, Hepatocellular/surgery*;
Chemoembolization, Therapeutic;
Combined Modality Therapy;
Hepatectomy;
Humans;
Liver Neoplasms/surgery*;
Neoplasm Recurrence, Local
- From:
Chinese Medical Journal
2021;134(19):2275-2286
- CountryChina
- Language:English
-
Abstract:
Surgical resection (SR) is recommended as a radical procedure in the treatment of hepatocellular carcinoma (HCC). However, postoperative recurrence negatively affects the long-term efficacy of SR, and preoperative adjuvant therapy has therefore become a research hotspot. Some clinicians adopt transcatheter arterial chemoembolization (TACE) as a preoperative adjuvant therapy in patients undergoing SR to increase the resection rate, reduce tumor recurrence, and improve the prognosis. However, the findings of the most relevant studies remain controversial. Some studies have confirmed that preoperative TACE cannot improve the long-term survival rate of patients with HCC and might even negatively affect the resection rate. Which factors influence the efficacy of preoperative TACE combined with SR is a topic worthy of investigation. In this review, existing clinical studies were analyzed with a particular focus on several topics: screening of the subgroups of patients most likely to benefit from preoperative TACE, exploration of the optimal treatment regimen of preoperative TACE, and determination of the extent of tumor necrosis as the deciding prognostic factor.
